EFFECT OF METFORMIN AND PYOGLITAZON ON THE RISK FACTORS OF CARDIOVASCULAR PATHOLOGY DIAGNOSED DURING SCREENING OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

Abstract

Under assessment there was metformin and pyoglitazon effect on the risk factors of cardiovascular disease. During treatment of patients with screening-diagnosed type 2 diabetes mellitus, the following changes were noted: decreasing the levels of glycated hemoglobin, Willebrand factor and C-reactive protein, and increasing the level of HDL cholesterol. It was shown that 6-month-long therapy with metformin and pyoglItazon allowed significant improving glycemia control and influencing markers of cardiovascular risk in these patients.

Keywords

• cardiovascular disease risk
• willebrand factor
• с-reactive protein